These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16463254)

  • 1. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of pharmacokinetic sampling schedules in clinical phase I trials: a use of Kullback-Leibler information.
    Yafune A; Ishiguro M
    Stat Med; 2001 Apr; 20(7):1033-49. PubMed ID: 11276034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
    Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simulation-based confidence band for drug concentrations in blood: an application to a clinical phase I trial.
    Yafune A; Ishiguro M
    Stat Med; 2003 Oct; 22(19):3045-53. PubMed ID: 12973786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic measures, their estimation and selection of sampling times.
    Fedorov V; Leonov S
    J Biopharm Stat; 2007; 17(5):919-41. PubMed ID: 17885874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved approach for confirmatory phase III population pharmacokinetic analysis.
    Hu C; Zhou H
    J Clin Pharmacol; 2008 Jul; 48(7):812-22. PubMed ID: 18490499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of sampling times for therapeutic drug monitoring.
    Mason GD; Winter ME
    Am J Hosp Pharm; 1984 Sep; 41(9):1796-801. PubMed ID: 6496515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
    Duffull SB; Graham G; Mengersen K; Eccleston J
    J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
    Ariano RE; Zelenitsky SA; Nyhlén A; Sitar DS
    J Clin Pharmacol; 2005 Jul; 45(7):832-5. PubMed ID: 15951473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of population pharmacokinetic experiments using prior information.
    Ogungbenro K; Aarons L
    Xenobiotica; 2007; 37(10-11):1311-30. PubMed ID: 17968747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.